News

Leap Therapeutics Set to Reveal DeFianCe Study Findings Soon

Leap Therapeutics Set to Reveal DeFianCe Study Findings Soon

Significant Announcement from Leap Therapeutics

Leap Therapeutics, Inc. (NASDAQ: LPTX), a pioneering biotechnology firm in the realm of targeted and immuno-oncology treatments, has exciting news to share. They are gearing up to unveil the final clinical outcomes from Part B of the DeFianCe study, a pivotal phase 2 trial. This highly anticipated data presentation will occur during a Mini Oral Session at the upcoming European Society for Medical Oncology (ESMO) Congress held in Berlin.

Details of the Mini Oral Session

This Mini Oral Session is expected to attract considerable interest as it will detail findings from the DeFianCe Trial. Titled "DeFianCe Trial: A randomized phase 2 trial of sirexatamab (DKN-01) plus bevacizumab and chemotherapy versus bevacizumab and chemotherapy as second-line therapy in advanced microsatellite stable (MSS) colorectal cancer (CRC)," the session will be presented by Zev A. Wainberg, M.D., an esteemed figure in the medical community and Co-Director of the GI Oncology Program at UCLA.

About the DeFianCe Study

The DeFianCe study is designed to evaluate the efficacy of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, when used in combination with bevacizumab and conventional chemotherapy. This trial uniquely compares the outcomes of patients receiving this innovative treatment against those treated solely with bevacizumab and chemotherapy. The focus is on patients suffering from advanced microsatellite stable colorectal cancer who have previously undergone one systemic therapy for their condition.

Clinical Implications of the Findings

The results presented will provide critical insights into the effectiveness of novel therapeutic combinations in treating advanced CRC—knowledge that may influence future treatment protocols. Efficacy and safety results can significantly impact clinical practices and offer new hope for patients facing challenging diagnoses. By pushing the boundaries of current treatment methodologies, Leap Therapeutics aims to enhance patient outcomes and pave the way for future oncology treatments.

Expectations Ahead of the Congress

The ESMO Congress is a platform where cutting-edge research is shared amongst leading medical professionals and researchers. The presentation will take place on October 19, 2025, at 4:05 p.m. CEST in Cologne Auditorium – CityCube A.

Leap Therapeutics' Commitment

Leap Therapeutics remains dedicated to advancing its pipeline of targeted therapies which includes both the sirexatamab and FL-501 monoclonal antibodies. These innovative treatments target crucial proteins believed to play significant roles in the growth of various cancers.

Company Overview

With a strong focus on unleashing the potential of immuno-oncology, Leap Therapeutics continues to build upon its foundational research. Investors and partners alike are eager for updates as the company navigates through clinical developments that could redefine the landscape of cancer treatment.

Frequently Asked Questions

What is the DeFianCe Study?

The DeFianCe Study is a Phase 2 clinical trial investigating the efficacy of sirexatamab combined with bevacizumab and chemotherapy in treating advanced colorectal cancer.

Who is presenting the findings?

The session will be presented by Dr. Zev A. Wainberg, a prominent figure in the field of oncology.

When will the findings be presented?

The findings will be presented at the ESMO Congress on October 19, 2025, at 4:05 p.m. CEST.

What is the target patient population for the trial?

The trial specifically targets patients with advanced microsatellite stable colorectal cancer who have had prior systemic therapy.

What are the key focuses of Leap Therapeutics?

Leap Therapeutics focuses on developing targeted and immunotherapy approaches aimed at improving outcomes for cancer patients.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Feeding Families Foundation Gains $121,500 for NYC Push

Updated Category News Views 6

Holy smokes, here comes some good news in the nonprofit corners! Feeding Families Foundation just got a hefty $121,500 boost from the Association of Contracting Plumbers of the City of New York Inc. This ain't just some pocket change; it's a full-fledged lifeline that helps them keep on delivering meals to parents who are practically living at their kid’s hospital...

Continue Reading
NOAA Taps ICEYE US for Game-Changing SAR Satellite Data

Updated Category News Views 8

The Strategic Move to SAR Data Imagine this: You’re in the thick of a hurricane, where visibility goes out the window, and traditional satellite data chokes under the crushing weight of clouds and nightfall. That's the precise chaos ICEYE US is cutting through with its Synthetic Aperture Radar (SAR) technology. The latest scuttlebutt is that NOAA's getting cozy with...

Continue Reading
WellLink Advisory Board Eyes Future of Healthcare Innovation

Updated Category News Views 5

Strategic Collaboration for Healthcare Evolution Ready to shake things up in healthcare, WellLink is setting the stage with its brand new Advisory Board. This move isn’t just about having fancy titles sitting around a conference table — it's about grabbing onto the future with both hands and figuring out just what the heck the healthcare industry needs next....

Continue Reading
Koogler's Sale to ALL4: A Game-Changer for the Southeast

Updated Category News Views 5

A Strategic Alignment Unfolds in Environmental Engineering Ever notice how those industry shifts often sneak up on you, only to leave a mark that's hard to ignore? That's exactly what's playing out with Koogler & Associates' recent hookup with ALL4 LLC. Set aside that coffee, this one's too important to miss if you've got a stake in the environmental consulting game or...

Continue Reading
TGI Fridays Unveils New 3 For All Menu Options

Updated Category News Views 10

Hedging Bets on New Dining Strategies Oh, the restaurant battlefield—where one day you're the toast of the town, and the next, you're hustling to keep those seats filled. TGI Fridays, a name as synonymous with casual eats as long as I’ve been in this game, is rolling the dice with a new offering dubbed '3 For All.' Doesn't sound like your average meal deal either....

Continue Reading
B2B Growth Hinges on Narrative Coherence, Study Shows

Updated Category News Views 5

Clear Stories, Stronger Growth If companies can't tell a clear story that their buyers understand and believe, they're destined to stagnate. That's the blunt reality kompeld is pushing with their H2 2026 Narrative Coherence Benchmark. The report scores 150 B2B tech companies on their narrative coherence, showing there's a stark correlation between storytelling and growth....

Continue Reading
Lyric Health's AI System Promises Data-Driven Revolution

Updated Category News Views 3

A Bold Step in Healthcare Coordination No doubt about it, healthcare is a mess. It's like trying to patch a leaking ship with duct tape—point solutions here, add-ons there, and nothing truly working in harmony. And in storms in Lyric Health, claiming they've got the answer. They've launched an AI-powered Healthcare Operating System meant to unify these disjointed pieces...

Continue Reading
Avive Partners with Cambridge Fire for Lifesaving Training

Updated Category News Views 8

Tapping into the Pulse: Avive & Cambridge Fire in Action No fooling around here—Avive Solutions is linking arms with the Cambridge Fire Department to put the city on a faster track to becoming a lifesaver haven. They're rolling out a free CPR and AED training right in the Smith Campus Center, Harvard Square. It's the kind of thing you love to see—getting the community...

Continue Reading
NY Sheriffs' Court Battle: Immigration Policies Under Fire

Updated Category News Views 10

Sheriffs Clash with State Over Immigration Policies In a tense showdown reminiscent of an old-time standoff, 15 New York county sheriffs have drawn their battle lines against the state’s capricious maneuvers by pushing a federal court to hit the brakes on Albany’s newly minted immigration rule. The so-called “Local Cops, Local Crimes Act” is catching serious heat,...

Continue Reading
Medicare Competitive Bidding May Slash Jobs, Access

Updated Category News Views 3

Medicare's New Program: Potential Knockout Punch? Today, we dive into Medicare's latest shake-up that might just be the unseen wrecking ball swinging toward thousands of jobs and small businesses in the healthcare sector. Two years from now, starting January 2028, the Competitive Bidding Program is set to reroute the entire landscape for suppliers of key medical products...

Continue Reading

Top 5 Most Recently Viewed Articles

New Clean Fuel Tax Credits Expected Amid Leadership Change

Updated Category News Views 254

Release of Short-Term Guidance on Clean Fuel Tax Credits The Biden administration is set to unveil short-term guidance regarding clean fuel tax credits. This announcement has created significant interest among biofuel companies that have been eyeing potential benefits from this initiative. Implications for Biofuel Producers With this upcoming guidance, biofuel producers...

Continue Reading
Oma Savings Bank’s Q1 Report Highlights and Future Strategy

Updated Category News Views 113

Oma Savings Bank Plc’s Financial Outcomes and Strategic Initiatives In the latest interim report, Oma Savings Bank Plc has detailed the financial performance for the first quarter. The results highlight several challenges, including elevated operational costs and falling market interest rates, which have collectively influenced profit margins. An extensive effort is...

Continue Reading
Pinnacle Financial Partners Ranks Among Top Workplaces for Women

Updated Category News Views 100

Pinnacle Financial Partners Ranks Among Top Workplaces for Women Pinnacle Financial Partners has earned a prestigious spot as one of the best workplaces for women, marked by its recent recognition as No. 8 on the esteemed 2024 Fortune Best Workplaces for Women list. This accolade, marking the seventh occurrence of this honor, is a testament to the firm’s unwavering...

Continue Reading
Analysts Adjust J.Jill's Stock Forecast After Q2 Results

Updated Category News Views 62

J.Jill's Second Quarter Performance Overview J. Jill Inc (NYSE: JILL) has recently shared its Q2 earnings report, showcasing results that surpassed expectations in both earnings and sales. The retail company faced a slight year-over-year sales decline of 0.9%, with total sales reaching $155.24 million, which exceeded the analysts' forecast of $154.23 million. This...

Continue Reading
Colgate-Palmolive Adjusts Price Target Despite Strong Earnings

Updated Category News Views 178

Overview of Colgate-Palmolive's Stock Analysis Recently, TD Cowen made a notable adjustment to its outlook on Colgate-Palmolive Company (NYSE: CL), reducing its price target from $115 to $110. Despite this modification, the firm continues to maintain a Buy rating for the stock. This price target adjustment was prompted by the company’s impressive performance in its...

Continue Reading